<?xml version='1.0' encoding='utf-8'?>
<document id="28737453"><sentence text="The metabolism and drug-drug interaction potential of the selective prostacyclin receptor agonist selexipag."><entity charOffset="68-80" id="DDI-PubMed.28737453.s1.e0" text="prostacyclin" /></sentence><sentence text="1" /><sentence text="窶サhe metabolism of selexipag has been studied in vivo in man and the main excreted metabolites were identified" /><sentence text=" Also, metabolites circulating in human plasma have been structurally identified and quantified" /><sentence text=" 2" /><sentence text="窶サhe main metabolic pathway of selexipag in man is the formation of the active metabolite ACT-333679" /><sentence text=" Other metabolic pathways include oxidation and dealkylation reactions" /><sentence text=" All primary metabolites undergo subsequent hydrolysis of the sulphonamide moiety to their corresponding acids"><entity charOffset="62-74" id="DDI-PubMed.28737453.s8.e0" text="sulphonamide" /></sentence><sentence text=" ACT-333679 undergoes conjugation with glucuronic acid and aromatic hydroxylation to P10, the main metabolite detected in human faeces"><entity charOffset="39-54" id="DDI-PubMed.28737453.s9.e0" text="glucuronic acid" /><entity charOffset="59-67" id="DDI-PubMed.28737453.s9.e1" text="aromatic" /><pair ddi="false" e1="DDI-PubMed.28737453.s9.e0" e2="DDI-PubMed.28737453.s9.e0" /><pair ddi="false" e1="DDI-PubMed.28737453.s9.e0" e2="DDI-PubMed.28737453.s9.e1" /></sentence><sentence text=" 3" /><sentence text="窶サhe formation of the active metabolite ACT-333679 is catalysed by carboxylesterases, while the oxidation and dealkylation reactions are metabolized by CYP2C8 and CYP3A4" /><sentence text=" CYP2C8 is the only P450 isoform catalysing the aromatic hydroxylation to P10" /><sentence text=" CYP2C8 together with CYP3A4 are also involved in the formation of several minor ACT-333679 metabolites" /><sentence text=" UGT1A3 and UGT2B7 catalyse the glucuronidation of ACT-333679" /><sentence text=" 4" /><sentence text="窶サhe potential of selexipag to inhibit or induce cytochrome P450 enzymes or drug transport proteins was studied in vitro" /><sentence text=" Selexipag is an inhibitor of CYP2C8 and CYP2C9 and induces CYP3A4 and CYP2C9 in vitro" /><sentence text=" Also, selexipag inhibits the transporters OATP1B1, OATP1B3, OAT1, OAT3, and BCRP" /><sentence text=" However, due to its low dose and relatively low unbound exposure, selexipag has a low potential for causing drug-drug interactions" /><sentence text="" /></document>